Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study

BACKGROUND: Daratumumab (Dara) is generally well tolerated, but is associated with increased risk of infection. METHODS: We investigated hypogammaglobinemia occurrence in different Dara-based regimens. Multiple myeloma (MM) patients were treated with ⩾2 cycles of Dara-based therapy during 2016–2020,...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitkon, Roy, Netanely, Dan, Levi, Shai, Ziv-Baran, Tomer, Ben-Yzak, Ronit, Katz, Ben-Zion, Benyamini, Noam, Trestman, Svetlana, Mittelman, Moshe, Cohen, Yael, Avivi, Irit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323447/
https://www.ncbi.nlm.nih.gov/pubmed/34377384
http://dx.doi.org/10.1177/20406207211035272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323447/
https://www.ncbi.nlm.nih.gov/pubmed/34377384
http://dx.doi.org/10.1177/20406207211035272

Ejemplares similares